Home › Researcher directory › Christopher E. Rudd

Christopher E. Rudd

Affiliation : Hôpital Maisonneuve-Rosemont · McGill University · Université de Montréal

• 5Publications (affiliation in Canada)
• 284Total publications
• 16682Citations
• 70h-index

ORCIDOpenAlex

Research profile

Christopher E. Rudd has 5 indexed publications (2022–2025). Their work appears mainly in “Communications Biology”, “Computational Toxicology” and “Heliyon”. Their most cited article, “Design and prediction of novel pyrazole derivatives as potential anti-cancer compounds based on 2D-QSAR study against PC-3, B16F10, K562, MD” (2022), has been cited 15 times. 2 of these publications date from the last three years of activity. Their work is co-authored with at least 9 researchers, including institutions in Morocco.

Is this you? Get your research seen

Create your free DzCademia profile and add your articles: they will show up more easily on Google and in AI assistants like ChatGPT, so more people can read and cite your work.

Create my free profile Add my publications

Research areas

• T-cell and B-cell Immunology
• Cancer Immunotherapy and Biomarkers
• Protein Kinase Regulation and GTPase Signaling
• Immunotherapy and Immune Responses
• Signaling Pathways in Disease

Publications (5)

• The identification of a SARs-CoV2 S2 protein derived peptide with super-antigen-like stimulatory properties on T-cells
  2025 · Communications Biology · cited 9 times
• 2D-QSAR study and design of novel pyrazole derivatives as an anticancer lead compound against A-549, MCF-7, HeLa, HepG-2, PaCa-2, DLD-1
  2023 · Computational Toxicology · cited 11 times
• Design and prediction of novel pyrazole derivatives as potential anti-cancer compounds based on 2D-QSAR study against PC-3, B16F10, K562, MDA-MB-231, A2780, ACHN and NUGC cancer cell lines
  2022 · Heliyon · cited 15 times
• In Silico Identification of Promising New Pyrazole Derivative-Based Small Molecules for Modulating CRMP2, C-RAF, CYP17, VEGFR, C-KIT, and HDAC—Application towards Cancer Therapeutics
  2022 · Current Issues in Molecular Biology · cited 11 times
• Targeting EGFR, RSK1, RAF1, PARP2 and LIN28B for several cancer type therapies with newly synthesized pyrazole derivatives via a computational study
  2022 · Journal of Biomolecular Structure and Dynamics · cited 7 times

Publication venues

• Communications Biology × 1
• Computational Toxicology × 1
• Heliyon × 1
• Current Issues in Molecular Biology × 1
• Journal of Biomolecular Structure and Dynamics × 1

Publications per year

• 20251
• 20231
• 20223

Collaborations

Partner institutions : Mohammed V University · McGill University Health Centre · Hôpital Maisonneuve-Rosemont Foundation

Co-authors’ countries : Morocco

Co-authors

• Fatima Ezzahra Bennani
• Ami Grunbaum
• Chen Liu
• Richard B. Kremer
• Denis‐Claude Roy
• Thai Hien Tu
• Nasser Masroori
• Catalin Milhalcioiu
• Nicholas Rozza

Bibliographic data from OpenAlex (open database).